JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
Jaroslav Žák(Scripps Research Institute), John R. Teijaro(Scripps Research Institute), Qing Cao(University of Minnesota), Livia Hegerova(University of Washington), Vaishalee P. Kenkre(University of Wisconsin–Madison), Reza Beheshti Zavareh(Ontario Institute for Cancer Research), Isaraphorn Pratumchai(Scripps Research Institute), Kristi Marquardt(Scripps Research Institute), Luke L. Lairson(Scripps Research Institute), Veronika Bachanová(University of Minnesota), Brett S. Marro(Scripps Research Institute), Michael B. A. Oldstone(Scripps Research Institute), Umar Farooq(Wake Forest University), Judith A. Varner(University of California San Diego)
Cited by 173
Related Papers
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
Molecular mimicry and immune‐mediated diseases
|The FASEB Journal|1998|605
The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule
|Proceedings of the National Academy of Sciences|2012|594
Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments.
|Proceedings of the National Academy of Sciences|1983|361
Integrin CD11b activation drives anti-tumor innate immunity
|Nature Communications|2018|313